Proteome Sciences plc (LON:PRM – Get Free Report)’s share price shot up 3.4% during mid-day trading on Friday . The stock traded as high as GBX 5 ($0.06) and last traded at GBX 4.64 ($0.06). 485,157 shares were traded during trading, an increase of 165% from the average session volume of 183,230 shares. The stock had previously closed at GBX 4.49 ($0.06).
Proteome Sciences Stock Up 3.4 %
The company has a current ratio of 0.20, a quick ratio of 0.37 and a debt-to-equity ratio of -258.66. The stock’s fifty day simple moving average is GBX 3.84 and its 200-day simple moving average is GBX 3.26. The stock has a market capitalization of £13.71 million, a PE ratio of -3.36 and a beta of 0.07.
About Proteome Sciences
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.
Featured Articles
- Five stocks we like better than Proteome Sciences
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- These 3 Defensive Retail Stocks Are Outpacing the Market
- What Are Dividend Achievers? An Introduction
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
Receive News & Ratings for Proteome Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteome Sciences and related companies with MarketBeat.com's FREE daily email newsletter.